Kinoxis Therapeutics Signs a License Agreement with Boehringer Ingelheim to Develop Novel Treatments for Psychiatric Patients with Social Dysfunction Symptoms
- Kinoxis will receive an up front & research support, ~$181M in milestones along with royalties on future Boehringer Ingelheim product sales. The companies collaborated to develop oxytocin targeting precision psychiatry treatments for neuropsychiatric disorders
- The collaboration will use chemical compounds developed by Kinoxis that target the oxytocin receptor. Kinoxis’ KNX100 is being developed for the mitigation of opioid withdrawal symptoms & treatment of agitation and aggression in neurodegenerative and neurodevelopmental disorders
- Kinoxis has received funding from the US National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms
Ref: Kinoxis Therapeutics | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].